CN1832732A - 用于治疗帕金森氏症的含有活性物质组合的经皮药物制剂 - Google Patents

用于治疗帕金森氏症的含有活性物质组合的经皮药物制剂 Download PDF

Info

Publication number
CN1832732A
CN1832732A CNA2004800225495A CN200480022549A CN1832732A CN 1832732 A CN1832732 A CN 1832732A CN A2004800225495 A CNA2004800225495 A CN A2004800225495A CN 200480022549 A CN200480022549 A CN 200480022549A CN 1832732 A CN1832732 A CN 1832732A
Authority
CN
China
Prior art keywords
active substance
combination
pharmaceutical preparation
group
selegiline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800225495A
Other languages
English (en)
Chinese (zh)
Inventor
米迦勒·霍斯特曼
弗兰克·提奥巴尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1832732(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of CN1832732A publication Critical patent/CN1832732A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2004800225495A 2003-08-20 2004-08-14 用于治疗帕金森氏症的含有活性物质组合的经皮药物制剂 Pending CN1832732A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10338174A DE10338174A1 (de) 2003-08-20 2003-08-20 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10338174.0 2003-08-20

Publications (1)

Publication Number Publication Date
CN1832732A true CN1832732A (zh) 2006-09-13

Family

ID=34201721

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800225495A Pending CN1832732A (zh) 2003-08-20 2004-08-14 用于治疗帕金森氏症的含有活性物质组合的经皮药物制剂

Country Status (21)

Country Link
US (1) US8980308B2 (enExample)
EP (1) EP1656122B2 (enExample)
JP (2) JP2007502795A (enExample)
KR (1) KR20060065692A (enExample)
CN (1) CN1832732A (enExample)
AT (1) ATE446744T1 (enExample)
AU (1) AU2004266063B2 (enExample)
BR (1) BRPI0412054A (enExample)
CA (1) CA2535063C (enExample)
DE (2) DE10338174A1 (enExample)
DK (1) DK1656122T4 (enExample)
ES (1) ES2335771T5 (enExample)
IL (1) IL173712A (enExample)
MX (1) MXPA06001815A (enExample)
NZ (1) NZ545593A (enExample)
PL (1) PL1656122T5 (enExample)
PT (1) PT1656122E (enExample)
RU (1) RU2397757C2 (enExample)
SI (1) SI1656122T2 (enExample)
WO (1) WO2005018619A1 (enExample)
ZA (1) ZA200509779B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103622997A (zh) * 2013-11-22 2014-03-12 内蒙古医科大学 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物
CN101772346B (zh) * 2007-04-02 2014-05-07 帕金森氏病研究院 用于降低治疗副作用的方法和组合物
CN104510725A (zh) * 2015-01-22 2015-04-15 中国药科大学 一种普拉克索周效透皮贴剂及其制备方法
CN109310526A (zh) * 2016-10-07 2019-02-05 全崴生技股份有限公司 普拉克索经皮贴片系统与用法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
CA2678391C (en) 2007-01-31 2017-01-17 David Alexander Learmonth Dosage regimen for comt inhibitors
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
KR20190079705A (ko) * 2008-07-29 2019-07-05 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 화합물 및 그 약학적 조성물
RU2701731C2 (ru) 2009-04-01 2019-10-01 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
US9017723B2 (en) 2010-04-30 2015-04-28 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
EP3604299B1 (en) 2011-12-13 2023-07-26 Bial-Portela & CA, S.A. Chemical compound useful as intermediate for preparing a catechol-0-methyl transferase inhibitor
US20130197023A1 (en) * 2012-01-27 2013-08-01 California Institute Of Technology Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors
NZ706590A (en) 2012-11-02 2016-02-26 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
US10111879B2 (en) 2013-06-27 2018-10-30 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
EP2946775A1 (de) 2014-05-20 2015-11-25 LTS LOHMANN Therapie-Systeme AG Lavendelöl enthaltendes transdermales therapeutisches System
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
JPH0611698B2 (ja) 1984-12-19 1994-02-16 大正製薬株式会社 貼付剤
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
DE3710966A1 (de) 1986-04-16 1987-12-03 Degussa Synergistische kombination von amantadin und selegilin
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
HK1006281A1 (en) * 1992-07-28 1999-02-19 The Procter & Gamble Company Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
DE4332094C2 (de) * 1993-09-22 1995-09-07 Lohmann Therapie Syst Lts Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
IL122484A0 (en) 1995-06-07 1998-06-15 Noven Pharma Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
DE19626621A1 (de) 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
JPH11209271A (ja) 1998-01-23 1999-08-03 Nitto Denko Corp 経皮吸収製剤
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
DE60006069T2 (de) 1999-02-05 2004-07-29 Cipla Ltd. Topische sprays enthaltend eine filmbildende zusammensetzung
AU5325000A (en) 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
FR2798065B1 (fr) 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
JP2002097137A (ja) * 2000-07-19 2002-04-02 Junichi Sudo パーキンソン病の予防および／または治療剤
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
DE10066158B4 (de) 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
DE10064453A1 (de) 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
EP1325742A1 (en) 2001-05-08 2003-07-09 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
ATE251901T1 (de) 2001-05-08 2003-11-15 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101772346B (zh) * 2007-04-02 2014-05-07 帕金森氏病研究院 用于降低治疗副作用的方法和组合物
CN103622997A (zh) * 2013-11-22 2014-03-12 内蒙古医科大学 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物
CN104510725A (zh) * 2015-01-22 2015-04-15 中国药科大学 一种普拉克索周效透皮贴剂及其制备方法
CN109310526A (zh) * 2016-10-07 2019-02-05 全崴生技股份有限公司 普拉克索经皮贴片系统与用法
CN109310526B (zh) * 2016-10-07 2022-05-17 全崴生技股份有限公司 普拉克索经皮贴片系统与用法

Also Published As

Publication number Publication date
DE10338174A1 (de) 2005-03-24
JP2012092127A (ja) 2012-05-17
EP1656122B2 (de) 2012-11-28
AU2004266063B2 (en) 2010-04-08
RU2397757C2 (ru) 2010-08-27
US20070026054A1 (en) 2007-02-01
DE502004010303D1 (de) 2009-12-10
BRPI0412054A (pt) 2006-08-15
AU2004266063A1 (en) 2005-03-03
DK1656122T4 (da) 2013-03-11
US8980308B2 (en) 2015-03-17
CA2535063C (en) 2014-06-17
ZA200509779B (en) 2006-09-27
NZ545593A (en) 2009-09-25
SI1656122T1 (sl) 2010-02-26
EP1656122B1 (de) 2009-10-28
PL1656122T5 (pl) 2013-04-30
PL1656122T3 (pl) 2010-03-31
WO2005018619A1 (de) 2005-03-03
ATE446744T1 (de) 2009-11-15
SI1656122T2 (sl) 2013-03-29
ES2335771T3 (es) 2010-04-05
PT1656122E (pt) 2010-02-02
JP5827114B2 (ja) 2015-12-02
KR20060065692A (ko) 2006-06-14
RU2005141214A (ru) 2006-07-27
EP1656122A1 (de) 2006-05-17
MXPA06001815A (es) 2006-05-31
CA2535063A1 (en) 2005-03-03
JP2007502795A (ja) 2007-02-15
ES2335771T5 (es) 2013-03-26
IL173712A0 (en) 2006-07-05
IL173712A (en) 2010-11-30
DK1656122T3 (da) 2010-03-08

Similar Documents

Publication Publication Date Title
CN1832732A (zh) 用于治疗帕金森氏症的含有活性物质组合的经皮药物制剂
US20220395469A1 (en) Transdermal drug delivery system for ketamine
JP4925823B2 (ja) プラミペキソール活性剤を含む経皮治療システム
JP7003211B2 (ja) 日に１回の取り替えによるフェンタニルの経皮投与
JP2017519837A (ja) 経皮送達システム
CN113950356B (zh) 含罗替戈汀的贴附剂
NO331441B1 (no) Transdermal granistetron
US20160184246A1 (en) Transdermal drug delivery systems for agomelatine
EP1888002A1 (en) Transdermal method and patch for nausea
CN113710238A (zh) 透皮治疗系统
TWI876275B (zh) 含羅替戈汀之貼附劑
CN101180018B (zh) 用于治疗恶心的经皮的方法和贴片
JP2018535225A (ja) 経皮薬剤送達のためのシステムおよび方法
CN116056689A (zh) 艾司氯胺酮-混悬剂-tts
RU2791107C1 (ru) Трансдермальная терапевтическая система
TW202440077A (zh) 含有羅替戈汀之貼附劑及羅替戈汀穩定性提升方法
HK40025664A (en) Transdermal drug delivery system for ketamine
TW200820996A (en) Transdermal method and patch for emesis
JP2007045779A (ja) 外用貼付剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060913